Cart

No products in the cart.

100% Secure Checkout!

Coronavirus

SARS-CoV-2 (COVID-19) antibody testing

In February 2020, AffinityImmuno responded quickly to the COVID19 pandemic by performing immunizations to generate research antibodies. We have developed antibodies to the full length spike protein and the two subunits (S1 and S2). We have also developed a surrogate virus neutralization test that measures antibodies in plasma and serum capable preventing virus from binding the ACE2 protein. Our testing kit can be used at scale to rapidly monitoring population immunity and vaccine response and help inform lockdown exit strategies.

In February 2020, AffinityImmuno responded quickly to the COVID19 pandemic by performing immunizations to generate research antibodies. We have developed antibodies to the full length spike protein and the two subunits (S1 and S2). 

pharmacokinetic & immunogenicity

ELISAs

Our ELISA kits are used to measure pharmacokinetics and immunogenicity biologics. Our kits are sensitive, specific, and give highly reproducible results.

Monoclonal

Antibodies

AffinityImmuno Inc. supplies monoclonal antibodies that have a long history of use in vitro and in vivo for cell depletion, blocking, and activation studies.
CUSTOM CHICKEN POLYCLONALS

IgEasY

Our standard polyclonal chicken egg IgY antibody service is a 35 day immunization program, followed by 14 days of egg collection with the flexibility to continue IgY production thereafter. We offer a flexible immunization schedule and use serum and egg titers to guide the collection timing in order to ensure maximum quality and yield. Antibodies can be provided in the form of total IgY or affinity purified IgY. This process is scalable to meet your needs.

Our standard polyclonal chicken egg IgY antibody service is a 35 day immunization program, followed by 14 days of egg collection with the flexibility to continue IgY production thereafter.

SARS-CoV-2

Antibody testing

ELISA Kits

Pharmacokinetics & immunogenicity

Antibodies

& Custom Antibodies

IgEasY

Chicken Polyclonal Service

Coronavirus

SARS-CoV-2 (COVID-19) antibody testing

In February 2020, AffinityImmuno responded quickly to the COVID19 pandemic by performing immunizations to generate research antibodies. We have developed antibodies to the full length spike protein and the two subunits (S1 and S2). We have also developed a surrogate virus neutralization test that measures antibodies in plasma and serum capable preventing virus from binding the ACE2 protein. Our testing kit can be used at scale to rapidly monitoring population immunity and vaccine response and help inform lockdown exit strategies.

In February 2020, AffinityImmuno responded quickly to the COVID19 pandemic by performing immunizations to generate research antibodies. We have developed antibodies to the full length spike protein and the two subunits (S1 and S2). 

pharmacokinetic & immunogenicity

ELISAs

Our ELISA kits are used to measure pharmacokinetics and immunogenicity biologics. Our kits are sensitive, specific, and give highly reproducible results.

Monoclonal

Antibodies

AffinityImmuno Inc. supplies monoclonal antibodies that have a long history of use in vitro and in vivo for cell depletion, blocking, and activation studies.
CUSTOM CHICKEN POLYCLONALS

IgEasY

Our standard polyclonal chicken egg IgY antibody service is a 35 day immunization program, followed by 14 days of egg collection with the flexibility to continue IgY production thereafter. We offer a flexible immunization schedule and use serum and egg titers to guide the collection timing in order to ensure maximum quality and yield. Antibodies can be provided in the form of total IgY or affinity purified IgY. This process is scalable to meet your needs.

Our standard polyclonal chicken egg IgY antibody service is a 35 day immunization program, followed by 14 days of egg collection with the flexibility to continue IgY production thereafter.

Announcements

November 2020

AffinityImmuno Inc. receives third place in the BioInnovation Challenge sponsored by BioNova.

AffinityImmuno Inc. was one of eight semi-finalists that presented at the BIC pitch competition on November 3 and made it to the final round on November 4.

It was a great opportunity to showcase the work we have done in the battle against the COVID19 pandemic, particularly in the development of our SARS-CoV-2 spike protein-ligand binding assay (surrogate Virus Neutralization Test).

June 2020

AffinityImmuno participates in the Bio International Convention

April/May 2020

AffinityImmuno develops test to see if people are immune to the coronavirus.

Check out our articles in The Guardian and the CBC.

Cart

No products in the cart.

100% Secure Checkout!

stay informed!

Subscribe to receive product updates & promotions.